PTAB rules Gilenya dosing patent is valid
Attempts to bring generics of Novartis’ Gilenya (fingolimod) blockbuster to the US market eight years ahead of schedule have failed for now, with the US Patent Trial and Appeal (PTAB) ruling that a dosing patent shielding the multiple sclerosis drug should stand, rejecting challenges from Apotex, Argentum, Sun Pharma and Teva.
You may also be interested in...
The latest decision in US litigation with HEC Pharma over multiple sclerosis treatment Gilenya means that generics will be kept off the market for at least two years, according to originator Novartis.
The US Supreme Court has denied Argentum Pharmaceuticals’ petition for certiorari review of an unfavorable Federal Circuit decision that considered whether the generics player had the standing to appeal a PTAB ruling.
Zydus Cadila has clocked up two tentative and four final abbreviated new drug application approvals in a short amount of time, including for Boehringer Ingelheim’s Jentadueto and the discontinued verapamil hydrochloride for injection.